The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases

Hormone and Metabolic Research

Volumn 40, Issue 2, 2008, Pages 137-146

  Lonyai, A ^a   Kodama, S ^b   Burger, D ^a   Davis, M ^a   Faustman, D L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Hearing loss; Hox11; Regeneration; Sjogren's syndrome; Spleen; Type 1 diabetes

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOX11+; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; CANCER RESEARCH; CELL DIVISION; COMORBIDITY; EMBRYO DEVELOPMENT; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HEARING LOSS; HEMATOPOIESIS; HOMEOBOX; HOX11 GENE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; SJOEGREN SYNDROME; SPLEEN; STEM CELL; STEM CELL TRANSPLANTATION;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HOMEODOMAIN PROTEINS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS; SJOGREN'S SYNDROME; SPLEEN; STEM CELL TRANSPLANTATION; TISSUE THERAPY; TRANSCRIPTION FACTORS;

ANIMALIA; MUS;

EID: 40549112348     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1022560     Document Type: Review

References (55)